KDR and neoplasm: Ramucirumab is a new type of human immunoglobulin G (IgG) 1 monoclonal antibody that can specifically inhibit VEGFR2 and block its interaction with ligands, further inhibiting angiogenesis and inducing tumor cell apoptosis.47,48